[Effect of mestranol and chlormadinone acetate on TSH, T4, TBC and FT4 index in Turner syndrome].
In 19 patients with Turner's syndrome aged from 12 to 24 years (average age 17.0 years) the influence of mestranol and chlormadinone acetate on both basal and TRH stimulated TSH secretion, total thyroxine (T4), thyroxine binding capacity (TBC) and free thyroxine index (FT4-I) by means of sequential stimulation test (0.5 g arginine hydrochloride/kg body weight, 25 micrograms GnRH and 200 micrograms TRH) was investigated. These investigations were performed before hormonal substitution, during third to 5th cycles of treatment and 4 month after finishing treatment. TSH and T4 serum levels were determined by RIA, TBC by radio reagent assay. The FT4 index was calculated. Mean basal TSH levels both before, during and after hormonal treatment did not differ. Netto TSH level increase were somewhat higher in 8 of the 19 patients during hormonal treatment. TBC and T4 significantly increased under treatment. The rise of FT4 in a few patients under treatment could not be ensured statistically. After finishing treatment the levels of thyroid parameters decreased.
D000293:Adolescent; D000328:Adult; D001120:Arginine; D002648:Child; D002715:Chlormadinone Acetate / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008656:Mestranol / Q000627:therapeutic use*; D011863:Radioimmunoassay; D013972:Thyrotropin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone; D013974:Thyroxine / Q000097:blood*; D013975:Thyroxine-Binding Proteins / Q000378:metabolism*; D014424:Turner Syndrome / Q000097:blood / Q000188:drug therapy*
D013975:Thyroxine-Binding Proteins; D002715:Chlormadinone Acetate; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin; D001120:Arginine; D008656:Mestranol; D013974:Thyroxine
Der Einfluss von Mestranol und Chlormadinonazetat auf TSH, T4, TBC und FT4-Index beim Turner-Syndrom.